bearish

Wuxi Biologics (2269.HK) - The Business Update Has Torn Away the Last Fig Leaf

717 Views05 Dec 2023 08:55
WuXi Bio's business update has completely caused investors to lose confidence. There're doubts about whether future performance guidance can be achieved. It's time to consider the worst-case scenario.
Boomeranged on Tue, 12 Dec 2023 09:47
Even though WuXi Bio launches US$600 million share repurchase, share price doesn't stop falling.Obviously, recent business update has changed investors' expectations/confidence of the outlook.It also remains to be seen whether future performance will recover as expected. After the spin-off of WuXi XDC, WuXi Bio becomes increasingly unattractive. In extreme case, over 2x P/B ratio is not impossible
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
chart-bar
x